Navigation Links
Accumetrics Appoints John J. Young, MD Chief Medical Officer
Date:11/11/2008

SAN DIEGO, Nov. 11 /PRNewswire/ -- Accumetrics, Inc. has announced the appointment of John J. Young, MD as Chief Medical Officer for the company. Dr. Young will serve in a part-time capacity in addition to his current appointment as Professor of Medicine and Director of the Cardiovascular Innovations Program at The Ohio State University in Columbus, Ohio. Dr. Young will serve as the main liaison to practicing clinicians, as well as coordinating ongoing research efforts and educational strategies.

"We are very pleased to welcome John to Accumetrics," said Timothy Still, President and CEO of The Company. "We look forward to leveraging his unique experience as a clinical investigator, as well as clinical expertise to continue to grow our Company."

Prior to joining The Ohio State University Medical Center, Dr. Young was the Co-Director of Cardiovascular Research & Education at the Swedish Heart & Vascular Institute in Seattle, Washington. Prior positions included Associate Director of the Lindner Center for Research & Education, and Director of Interventional Services at the Ohio Heart & Vascular Center, both in Cincinnati, Ohio. Dr. Young received his M.D. from The Ohio State University College of Medicine, where he completed both his Residency and Fellowship training. He also holds a Bachelor of Science degree in chemistry, with honors, from Wright State University, Dayton, OH. Finally, Dr. Young has received the distinction of being one of the "Best Doctors in America," and is a lifetime member of "Who's Who in Medicine & Healthcare."

About Accumetrics (http://www.accumetrics.com)

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow(R) System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc., ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.

CONTACT:

Jules Abraham

Lippert/Heilshorn & Associates

212-838-3777

jabraham@lhai.com


'/>"/>
SOURCE Accumetrics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Timothy I. Still Appointed CEO at Accumetrics
2. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
3. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
4. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
5. NutraCea Appoints New Chief Financial Officer
6. Cardiac Science Appoints Dave Marver as Chief Operating Officer
7. Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response
8. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
9. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
10. Nikon Instruments Appoints LABSCO its Clinical Distributor in Six States
11. China Pharma Holdings, Inc. Appoints The Ruth Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, today reported preliminary evidence of cognitive ... investigational therapy for the treatment of Hurler and ... or MPS I). The initial results from an ... at the 13 th annual WORLD Symposium ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... SAN DIEGO , Feb. 16, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... $5 million Series 1a financing and entered into ... Bank (SVB).  Dermata intends to use the capital ... of making major advancements in the treatment of ...
Breaking Biology Technology:
(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):